EA202092263A1 - Аминопиридиновые производные в качестве ингибиторов ctps1 - Google Patents

Аминопиридиновые производные в качестве ингибиторов ctps1

Info

Publication number
EA202092263A1
EA202092263A1 EA202092263A EA202092263A EA202092263A1 EA 202092263 A1 EA202092263 A1 EA 202092263A1 EA 202092263 A EA202092263 A EA 202092263A EA 202092263 A EA202092263 A EA 202092263A EA 202092263 A1 EA202092263 A1 EA 202092263A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aminopyridine derivatives
ctps1 inhibitors
ctps1
inhibitors
aminopyridine
Prior art date
Application number
EA202092263A
Other languages
English (en)
Inventor
Абдул Куддус
Эндрю Новак
Дэвид Кузен
Эмма Блэкхэм
Джерент Джоунс
Джозеф Ригглесворт
Лорна Даффи
Луиз Бирч
Паскаль Жорж
Салех Ахмед
Original Assignee
Степ Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18163772.9A external-priority patent/EP3543232A1/en
Priority claimed from EP18175823.6A external-priority patent/EP3578551A1/en
Application filed by Степ Фарма С.А.С. filed Critical Степ Фарма С.А.С.
Priority claimed from PCT/EP2019/057320 external-priority patent/WO2019180244A1/en
Publication of EA202092263A1 publication Critical patent/EA202092263A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединение формулы (I)и родственные аспекты.
EA202092263A 2018-03-23 2019-03-22 Аминопиридиновые производные в качестве ингибиторов ctps1 EA202092263A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18163772.9A EP3543232A1 (en) 2018-03-23 2018-03-23 Aminopyrimidine derivatives as ctps1 inhibitors
EP18175823.6A EP3578551A1 (en) 2018-06-04 2018-06-04 Sulfonamide derivatives
EP18202136 2018-10-23
PCT/EP2018/086617 WO2019179652A1 (en) 2018-03-23 2018-12-21 Aminopyrimidine derivatives as ctps1 inhibitors
PCT/EP2019/057320 WO2019180244A1 (en) 2018-03-23 2019-03-22 Aminopyrimidine derivatives as ctps1 inhibitors

Publications (1)

Publication Number Publication Date
EA202092263A1 true EA202092263A1 (ru) 2021-01-15

Family

ID=64949297

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092263A EA202092263A1 (ru) 2018-03-23 2019-03-22 Аминопиридиновые производные в качестве ингибиторов ctps1

Country Status (18)

Country Link
US (1) US20210024507A1 (ru)
EP (1) EP3768674B1 (ru)
JP (2) JP7428692B2 (ru)
KR (1) KR20200135463A (ru)
CN (1) CN111868051B (ru)
AU (1) AU2018413791B2 (ru)
BR (1) BR112020018701A2 (ru)
CA (1) CA3093050A1 (ru)
DK (1) DK3768674T3 (ru)
EA (1) EA202092263A1 (ru)
FI (1) FI3768674T3 (ru)
IL (1) IL277455B2 (ru)
LT (1) LT3768674T (ru)
MX (1) MX2020009887A (ru)
PH (1) PH12020500655A1 (ru)
PL (1) PL3768674T3 (ru)
SG (1) SG11202103238XA (ru)
WO (1) WO2019179652A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106146A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3717459A1 (en) 2017-11-30 2020-10-07 Step Pharma S.A.S. Compounds
BR112021005986A2 (pt) 2018-10-23 2021-06-29 Step Pharma S.A.S. derivados de aminopirimidina como inibidores de ctps1
EP3980410A1 (en) 2019-06-04 2022-04-13 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
EP3980411A1 (en) * 2019-06-04 2022-04-13 Step Pharma S.A.S. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
WO2021053403A1 (en) 2019-09-20 2021-03-25 Step Pharma S.A.S. Sulfonamide inhibitors as ctps1 inhibitors
US20230002352A1 (en) 2019-09-20 2023-01-05 Step Pharma S.A.S. Sulfonamide derivatives as ctps1 inhibitors
WO2023166078A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
WO2023166076A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combinations of ctps1 and bcl2 inhibitors for cancer
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
WO2023166077A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070589A1 (es) * 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP2231602A1 (en) * 2007-12-13 2010-09-29 Amgen, Inc Gamma secretase modulators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
KR101097312B1 (ko) * 2009-08-10 2011-12-23 삼성모바일디스플레이주식회사 유기 발광 소자
WO2014170435A2 (en) * 2013-04-18 2014-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for inhibiting lymphocyte proliferation in a subject in need thereof
GB201322333D0 (en) * 2013-12-17 2014-01-29 Agency Science Tech & Res WNT pathway modulators
CA2956417C (en) * 2014-07-31 2022-09-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Flt3 receptor antagonists

Also Published As

Publication number Publication date
JP7428692B2 (ja) 2024-02-06
LT3768674T (lt) 2024-04-25
PL3768674T3 (pl) 2024-04-29
IL277455A (en) 2020-11-30
US20210024507A1 (en) 2021-01-28
EP3768674B1 (en) 2024-01-03
DK3768674T3 (da) 2024-02-19
CA3093050A1 (en) 2019-09-26
AU2018413791A1 (en) 2020-09-17
WO2019179652A1 (en) 2019-09-26
SG11202103238XA (en) 2021-04-29
PH12020500655A1 (en) 2021-06-21
AU2018413791B2 (en) 2023-05-18
IL277455B1 (en) 2024-01-01
EP3768674A1 (en) 2021-01-27
IL277455B2 (en) 2024-05-01
CN111868051B (zh) 2024-04-09
BR112020018701A2 (pt) 2020-12-29
KR20200135463A (ko) 2020-12-02
JP2021518436A (ja) 2021-08-02
MX2020009887A (es) 2020-10-12
JP2024020222A (ja) 2024-02-14
FI3768674T3 (fi) 2024-04-02
CN111868051A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
EA201991503A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
MX2020009347A (es) Picolinamidas como fungicidas.
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA202092451A1 (ru) Соединения
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201792021A1 (ru) Ингибитор jak
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
EA201991700A1 (ru) Селективные ингибиторы jak1
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA201592183A1 (ru) Ингибиторы bace
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
EA201992306A1 (ru) Ингибиторы ip6k